Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 7/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805094 | 0.83 | LIMK1 (0.35) | PRKCIKDM4EMAPTSMN1; SMN2PIK3CA | |
| SCHEMBL19805185 | 0.83 | PRKCI (0.48) | PRKCIHTR2CTP53CYP1A2CYP3A4 | |
| SCHEMBL19805096 | 0.83 | PRKCI (0.48) | PRKCIHTR2CCYP1A2CYP2D6PIK3CA | |
| SCHEMBL19805169 | 0.81 | PRKCI (0.46) | PRKCIHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL19805137 | 0.81 | HTR2C (0.62) | PRKCIHTR2CKDM4ETSHRPIK3CA | |
| SCHEMBL19805168 | 0.77 | PRKCI (0.44) | PRKCIHTR2CKDM4EPIK3CALIMK1 | |
| SCHEMBL19805099 | 0.72 | PRKCI (0.44) | PRKCIHTR2CKDM4ETP53CYP1A2 | |
| SCHEMBL19805165 | 0.70 | GUSB (0.44) | PRKCIHTR2CKDM4ETP53CYP1A2 | |
| SCHEMBL5730721 | 0.69 | PRKCI (0.56) | PRKCIHTR2CKDM4EMAPTTOP1 | |
| SCHEMBL5731659 | 0.69 | HTR2C (0.62) | PRKCIHTR2CMAPTTOP1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2018142365-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018017874-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | GUSB, ENGASE, MGAM | PRKCI 3195/4885HTR2C 4260/4885KDM4E 4075/4885 |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | GUSB, ENGASE, MGAM | PRKCI 3195/4885HTR2C 4260/4885KDM4E 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.